Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
10.38
-0.10 (-0.95%)
At close: Mar 28, 2025, 4:00 PM
10.30
-0.08 (-0.76%)
Pre-market: Mar 31, 2025, 8:41 AM EDT
Roivant Sciences Employees
Roivant Sciences had 908 employees as of March 31, 2024. The number of employees increased by 4 or 0.44% compared to the previous year.
Employees
908
Change (1Y)
4
Growth (1Y)
0.44%
Revenue / Employee
$135,006
Profits / Employee
-$128,437
Market Cap
7.41B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 908 | 4 | 0.44% |
| Mar 31, 2023 | 904 | 41 | 4.75% |
| Mar 31, 2022 | 863 | 198 | 29.77% |
| Jun 30, 2021 | 665 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ROIV News
- 12 days ago - Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies - GlobeNewsWire
- 12 days ago - Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs - GlobeNewsWire
- 27 days ago - Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna - GlobeNewsWire
- 6 weeks ago - Roivant Sciences Ltd. (ROIV) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update - GlobeNewsWire
- 7 weeks ago - Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade) - Seeking Alpha
- 2 months ago - Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care - GlobeNewsWire
- 2 months ago - Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025 - GlobeNewsWire